DIACEUTICS PLC

Director's Dealing • May 27, 2022

National Storage Mechanism | Additional information

RNS Number : 1410N

Diaceutics PLC

27 May 2022

27 May 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Issue of and changes to Share Options/PDMR Shareholdings

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of 200,000 share options over ordinary shares of £0.002 each in the Company ("Share Options") to certain directors and members of the Company's senior management team as part of their remuneration package and pursuant to the Company's Employee Share Option Plan ("ESOP"), and provides an update on the arrangements for the share options held by Philip White.

Share Options were granted as follows:

Name	Number of Share Options granted	Total no. of ordinary shares under option post grant	% of existing issued share capital	Effective Grant date
Nick Roberts, CFO	50,000	91,838	0.10%	27 May 2022
Julie Browne, COO and PDMR	50,000	101,938	0.12%	27 May 2022
Stefan McDonald, CGO and PDMR	50,000	131,722	0.16%	27 May 2022
Other employees (1 person)	50,000	96,051	0.11%	27 May 2022

The Share Options issued to the Director and CFO, Nick Roberts, vest over three years from the point of employment start (being 18th March 2022) and are subject to continued employment.

The Share Options issued to Julie Browne and the other employee vest in tranches over a three-year period from the point of employment start (being 14th March 2022 and 1st January 2022 respectively), and to Stefan McDonald from the date of his promotion to the Company's senior management team (being 1st September 2021) and are subject to continued employment.

The exercise price of the Share Options granted is £0.002 per share which equates to the nominal value of the shares.

Following this grant, the total number of share options outstanding in the Company is 3,308,118, representing approximately 3.92% of its current issued share capital of 84,472,431.

Further to the announcement on 11 January 2022 and, as part of the orderly handover of duties Phillip White (former CFO and Director) is facilitating, the Board has agreed that all his outstanding share options would vest immediately (including those which are currently out of the money). As provided in the scheme rules, these options are require to be exercised within 90 days of vesting.

Phillip White's outstanding share options are as follows:

Number of Share Options outstanding	Grant date	Exercise price (pence)	Original vesting period	Original vesting conditions
180,000	17 April 2020	126.5	3 years	Continued employment
64,154	20 April 2021	0.2	3 years	Total Shareholder Return and continued employment

The above arrangements with Philip White constitute a related party transaction under the AIM Rules for Companies.  The directors, excluding Philip White who is no longer a director, consider, having consulted with the Company's nominated adviser, Stifel Nicolaus Europe Limited, that the terms of the transaction are fair and reasonable insofar as the Company's shareholders are concerned.

Enquiries:

Diaceutics PLC
Peter Keeling, Chief Executive Officer	Via Alma PR
Nick Roberts, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: +44 (0)20 7710 7600
Ben Maddison, Stewart Wallace, Nick Adams
Alma PR	Tel: +44(0)20 3405 0205
Caroline Forde, Kieran Breheny, Matthew Young	diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Nick Roberts
2	Reason for notification
a.	Position/Status	CFO, Director
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Grant of share options
c.	Price(s) and volume(s)
	Price(s)	Volume(s)
Exercise price of 0.2p per share	50,000
e.	Date of the transaction	26 May 2022
f.	Place of the transaction	Outside a trading venue

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Julie Browne
2	Reason for notification
a.	Position/Status	COO and PDMR
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Grant of share options
c.	Price(s) and volume(s)
	Price(s)	Volume(s)
Exercise price of 0.2p per share	50,000
e.	Date of the transaction	26 May 2022
f.	Place of the transaction	Outside a trading venue

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Stefan McDonald
2	Reason for notification
a.	Position/Status	CGO and PDMR
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Grant of share options
c.	Price(s) and volume(s)
	Price(s)	Volume(s)
Exercise price of 0.2p per share	50,000
e.	Date of the transaction	26 May 2022
f.	Place of the transaction	Outside a trading venue

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Philip White
2	Reason for notification
a.	Position/Status	PDMR
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over new ordinary shares of 0.2p each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Change of original vesting conditions of share options
c.	Price(s) and volume(s)
	Price(s)	Volume(s)
Exercise price of 126.5p per share	180,000
	Exercise price of 0.2p per share	64,154
e.	Date of the transaction	26 May 2022
f.	Place of the transaction	Outside a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHARMATMTTTBPT